Peptide Library / Detail
Bronchogen
Half-life
Not established in published literature
Delivery
Subcutaneous or intramuscular injection
Dosage
—
Research Use Only
All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.
Purchase
Description
Bronchogen is a short synthetic tetrapeptide with the sequence Ala-Asp-Glu-Leu (ADEL) that acts as a biological regulator with specific affinity for bronchial and lung tissue. It belongs to a class of tissue-specific peptides that modulate gene expression and cellular differentiation. Research suggests it exerts protective and regenerative effects on bronchial epithelium, particularly in models of obstructive lung pathology.
Usage
Bronchogen is administered in research settings typically via subcutaneous or intramuscular injection. Studies have examined dosing protocols ranging from 10-100 μg per administration over periods of 10-30 days. The peptide has been studied primarily in animal models of chronic obstructive pulmonary conditions with administration once daily during active treatment phases.
Mechanism of Action
Bronchogen penetrates cell nuclei and interacts directly with DNA and deoxyribooligonucleotides, affecting DNA thermostability and modulating gene expression. It tissue-specifically regulates expression of CLE, KNOX1, and GRF family genes involved in cellular differentiation and tissue homeostasis. The peptide demonstrates anti-inflammatory properties and promotes morphofunctional restoration of bronchial epithelium by stimulating cell differentiation processes, particularly during aging or pathological conditions.
Benefits(7)
- Promotes regeneration and repair of bronchial epithelium
- Reduces inflammatory responses in lung tissue
- Improves morphofunctional state of airways in obstructive pathology
- Modulates tissue-specific gene expression related to cellular differentiation
- Enhances DNA stability in bronchial cells
- Supports cellular differentiation during aging processes
- Demonstrates tissue-specific targeting to pulmonary structures
Side Effects(5)
- Limited human safety data available
- Potential injection site reactions
- Unknown long-term effects in humans
- Possible immunogenic responses (theoretical)
- Effects on non-target tissues not fully characterized